{"id":53768,"date":"2026-01-12T21:02:02","date_gmt":"2026-01-12T13:02:02","guid":{"rendered":"https:\/\/flcube.com\/?p=53768"},"modified":"2026-01-12T21:02:03","modified_gmt":"2026-01-12T13:02:03","slug":"fda-announces-flexible-cmc-pathway-for-cell-and-gene-therapies-to-accelerate-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53768","title":{"rendered":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development"},"content":{"rendered":"\n<p>The <strong>FDA\u2019s Center for Biologics Evaluation and Research (CBER)<\/strong> announced a <strong>flexible, lifecycle\u2011based approach<\/strong> to overseeing <strong>chemistry, manufacturing, and control (CMC)<\/strong> requirements for <strong>cell and gene therapies (CGT)<\/strong>. The policy aims to <strong>expedite product development<\/strong> by allowing <strong>permissive release criteria<\/strong> in INDs, <strong>minor pre\u2011licensure manufacturing changes<\/strong>, and <strong>flexible product release specifications<\/strong> justified by post\u2011approval experience, addressing challenges posed by <strong>small patient populations<\/strong> and <strong>limited manufacturing lots<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-policy-overview\">Regulatory Policy Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Authority<\/strong><\/td><td>FDA Center for Biologics Evaluation and Research (CBER)<\/td><\/tr><tr><td><strong>Policy Scope<\/strong><\/td><td>Chemistry, Manufacturing, and Control (CMC) for Cell and Gene Therapies (CGT)<\/td><\/tr><tr><td><strong>Core Principle<\/strong><\/td><td>Lifecycle\u2011based approach with flexible specifications<\/td><\/tr><tr><td><strong>Key Flexibility<\/strong><\/td><td>Permissive IND release criteria; no fixed 3\u2011lot PPQ requirement<\/td><\/tr><tr><td><strong>Manufacturing Changes<\/strong><\/td><td>Minor changes allowed with comparability data<\/td><\/tr><tr><td><strong>Specifications<\/strong><\/td><td>Flexible release specs allowed in BLA reviews when justified<\/td><\/tr><tr><td><strong>Post\u2011Approval<\/strong><\/td><td>Specs can be revised based on consistent quality experience<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-policy-flexibilities\">Key Policy Flexibilities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-permissive-product-quality-release-criteria\"><strong>1. Permissive Product Quality Release Criteria<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND Phase<\/strong>: Manufacturers <strong>need not follow prior regulations<\/strong> for Phase\u202f2\/3 investigational products<\/li>\n\n\n\n<li><strong>Concurrent Release<\/strong>: CGT process validation allows <strong>concurrent product release<\/strong> without complete validation<\/li>\n\n\n\n<li><strong>Rationale<\/strong>: Final specifications are not set until trial completion, enabling <strong>adaptive manufacturing<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-process-performance-qualification-ppq-flexibility\"><strong>2. Process Performance Qualification (PPQ) Flexibility<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>No Fixed Lot Requirement<\/strong>: FDA <strong>eliminates the fixed 3\u2011lot PPQ rule<\/strong> for validation<\/li>\n\n\n\n<li><strong>Justification\u2011Based<\/strong>: CBER reviews if PPQ protocols <strong>justify proper lot number<\/strong> based on overall process understanding<\/li>\n\n\n\n<li><strong>Small Population Accommodation<\/strong>: Recognizes that <strong>small CGT patient populations limit manufacturing lots<\/strong> for release specs<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-manufacturing-change-management\"><strong>3. Manufacturing Change Management<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Minor Pre\u2011Licensure Changes<\/strong>: Allowed with <strong>comparability data<\/strong><\/li>\n\n\n\n<li><strong>Risk\u2011Based Assessment<\/strong>: Changes evaluated on <strong>impact to product quality, safety, and efficacy<\/strong><\/li>\n\n\n\n<li><strong>Timeline Savings<\/strong>: Reduces <strong>6\u201112 month delay<\/strong> traditionally required for manufacturing changes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-4-post-approval-specification-flexibility\"><strong>4. Post\u2011Approval Specification Flexibility<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BLA Review Flexibility<\/strong>: CBER will consider <strong>flexible product release specifications<\/strong> when scientifically justified<\/li>\n\n\n\n<li><strong>Revision Pathway<\/strong>: Allows <strong>post\u2011approval specification revisions<\/strong> based on accumulated manufacturing experience showing consistent quality<\/li>\n\n\n\n<li><strong>Lifecycle Approach<\/strong>: Aligns with FDA\u2019s <strong>Quality by Design (QbD)<\/strong> and <strong>continuous improvement<\/strong> principles<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-industry-implications\">Market Impact &amp; Industry Implications<\/h2>\n\n\n\n<p><strong>CGT Market Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global CGT Market<\/strong>: <strong>$12\u202fbillion<\/strong> (2025), projected <strong>$35\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>CMC Bottleneck<\/strong>: Manufacturing challenges account for <strong>40%<\/strong> of clinical delays and <strong>25%<\/strong> of BLA rejections<\/li>\n\n\n\n<li><strong>Cost Savings<\/strong>: Flexible CMC approach could <strong>reduce development costs by $20\u201130\u202fmillion<\/strong> per program and <strong>accelerate timelines by 12\u201118 months<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Industry Beneficiaries<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>CGT Pipeline<\/th><th>CMC Challenge Mitigation<\/th><th>Development Timeline Acceleration<\/th><\/tr><\/thead><tbody><tr><td><strong>CRISPR Therapeutics<\/strong><\/td><td>5 programs<\/td><td>High<\/td><td>12\u201115 months<\/td><\/tr><tr><td><strong>Bluebird Bio<\/strong><\/td><td>3 programs<\/td><td>High<\/td><td>10\u201112 months<\/td><\/tr><tr><td><strong>Kite\/Gilead<\/strong><\/td><td>4 programs<\/td><td>Medium<\/td><td>8\u201110 months<\/td><\/tr><tr><td><strong>Novartis<\/strong><\/td><td>2 programs<\/td><td>Medium<\/td><td>6\u20118 months<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Manufacturing Vendors<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CDMOs<\/strong> (Catalent, Lonza) will see <strong>15\u201120% increase<\/strong> in CGT manufacturing contracts as flexible specs reduce client validation burden<\/li>\n\n\n\n<li><strong>Equipment Suppliers<\/strong> (Sartorius, Cytiva) benefit from <strong>accelerated facility build\u2011outs<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-cgt-developers\">Strategic Implications for CGT Developers<\/h2>\n\n\n\n<p><strong>Regulatory Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Faster IND Filings<\/strong>: Permissive release specs enable <strong>rolling submissions<\/strong><\/li>\n\n\n\n<li><strong>Reduced Clinical Hold Risk<\/strong>: <strong>30\u201140% lower<\/strong> probability of CMC\u2011related clinical holds<\/li>\n\n\n\n<li><strong>BLA Readiness<\/strong>: Lifecycle approach ensures <strong>continuous BLA\u2011readiness<\/strong> vs. stop\u2011gap fixes<\/li>\n<\/ul>\n\n\n\n<p><strong>Investment Implications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation Uplift<\/strong>: CGT companies could see <strong>5\u201110% DCF increase<\/strong> due to derisked development timelines<\/li>\n\n\n\n<li><strong>M&amp;A Activity<\/strong>: Flexible CMC makes <strong>late\u2011stage CGT assets more attractive<\/strong>, potentially triggering <strong>$10\u201115\u202fbillion<\/strong> in M&amp;A in 2026\u20112027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the FDA\u2019s CMC policy implementation, its impact on CGT development timelines, and market dynamics. Actual results may differ materially due to regulatory interpretation variations, industry adaptation rates, and unforeseen manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[77,66],"class_list":["post-53768","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-policy-regulatory","tag-cell-therapy","tag-gene-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53768\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development\" \/>\n<meta property=\"og:description\" content=\"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53768\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T13:02:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T13:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development\",\"datePublished\":\"2026-01-12T13:02:02+00:00\",\"dateModified\":\"2026-01-12T13:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768\"},\"wordCount\":558,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Gene therapy\"],\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53768#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53768\",\"name\":\"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T13:02:02+00:00\",\"dateModified\":\"2026-01-12T13:02:03+00:00\",\"description\":\"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53768\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53768#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development - Insight, China&#039;s Pharmaceutical Industry","description":"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53768","og_locale":"en_US","og_type":"article","og_title":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development","og_description":"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.","og_url":"https:\/\/flcube.com\/?p=53768","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T13:02:02+00:00","article_modified_time":"2026-01-12T13:02:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53768#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53768"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development","datePublished":"2026-01-12T13:02:02+00:00","dateModified":"2026-01-12T13:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53768"},"wordCount":558,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Gene therapy"],"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53768#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53768","url":"https:\/\/flcube.com\/?p=53768","name":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T13:02:02+00:00","dateModified":"2026-01-12T13:02:03+00:00","description":"The FDA\u2019s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle\u2011based approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT). The policy aims to expedite product development by allowing permissive release criteria in INDs, minor pre\u2011licensure manufacturing changes, and flexible product release specifications justified by post\u2011approval experience, addressing challenges posed by small patient populations and limited manufacturing lots.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53768#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53768"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53768#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53768"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53768\/revisions"}],"predecessor-version":[{"id":53769,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53768\/revisions\/53769"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}